TPST
$TPST
Tempest Therapeutics, Inc.
Clinical-stage biotech exploring cannabinoid-related therapeutics for oncology.
Cannabis$0.76
-0.01 (-1.30%)
Day Range$0.76 - $0.77
Prev Close$0.77
Analyst Rating
Strong Buy
1 Buy / 0 Hold / 0 Sell
Subscribers
0
Tracking this ticker
Latest Report
Analysis from Apr 6, 2026
TPST: Dual-CAR T Acquisition, Clinical Catalysts
Tempest Therapeutics ($TPST) is a small-cap clinical-stage biotech with recent earnings beats and a strategic acquisition of dual-CAR T assets. Analysts are upbeat, but losses, dilution risk, and a collapsed share price leave the risk/reward mixed.
Apr 6, 2026